Cargando…
Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer
SIMPLE SUMMARY: Historically, the treatment of prostate cancer was a blanket approach for all. Prostate cancer has not benefitted from targeted treatments based on specific tumour characteristics (ie. Particular genetic or molecular patterns) the way other cancers have. This is important as studies...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616097/ https://www.ncbi.nlm.nih.gov/pubmed/34830851 http://dx.doi.org/10.3390/cancers13225697 |